Published in J Am Coll Cardiol on October 17, 2012
Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med (2014) 2.15
Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care (2014) 1.79
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther (2013) 1.07
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud (2013) 0.91
Lipid-lowering agents in chronic kidney disease: do fibrates have a role? Nat Rev Cardiol (2013) 0.91
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol (2015) 0.88
Lipid mediators in diabetic nephropathy. Fibrogenesis Tissue Repair (2014) 0.88
Association of uric acid, atherogenic index of plasma and albuminuria in diabetes mellitus. Int J Clin Exp Med (2014) 0.86
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
Fibrates and cardiorenal outcomes. J Am Coll Cardiol (2012) 0.83
Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud (2013) 0.81
Metabolic syndrome in children with chronic kidney disease and after renal transplantation. Pediatr Nephrol (2013) 0.78
Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence. Diabetes Metab Syndr Obes (2015) 0.78
Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials. Rev Diabet Stud (2013) 0.77
Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study. Diabetol Metab Syndr (2014) 0.77
Alteration of Fatty Acid Oxidation in Tubular Epithelial Cells: From Acute Kidney Injury to Renal Fibrogenesis. Front Med (Lausanne) (2015) 0.76
microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun (2017) 0.75
The impact of antihypertensives on kidney disease. F1000Res (2017) 0.75
Lipid lowering in renal disease. Aust Prescr (2017) 0.75
The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients. Clin Kidney J (2017) 0.75
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med (2012) 11.83
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10
Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med (2009) 9.77
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Relation between kidney function, proteinuria, and adverse outcomes. JAMA (2010) 8.26
The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science (2009) 8.23
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet (2013) 6.19
Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet (2012) 5.65
Chronic diseases now a leading cause of death in rural India--mortality data from the Andhra Pradesh Rural Health Initiative. Int J Epidemiol (2006) 5.60
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol (2008) 5.40
Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA (2007) 5.31
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (2009) 4.73
Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ (2011) 4.68
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis (2010) 4.28
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med (2014) 3.81
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.78
When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int (2009) 3.70
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Recommendations on screening for type 2 diabetes in adults. CMAJ (2012) 3.51
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med (2005) 3.44
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35
Recommendations on screening for cervical cancer. CMAJ (2013) 3.32
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26
Population Health Metrics Research Consortium gold standard verbal autopsy validation study: design, implementation, and development of analysis datasets. Popul Health Metr (2011) 3.21
The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil (2010) 3.20
Early recognition and prevention of chronic kidney disease. Lancet (2010) 3.19
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med (2011) 3.13
Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst (2006) 3.11
Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation (2005) 3.10
Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int (2013) 3.05
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int (2005) 3.03
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 3.02
How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ (2008) 3.00
Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation (2005) 2.97
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet (2010) 2.95
Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int (2008) 2.88
The health and well-being of caregivers of children with cerebral palsy. Pediatrics (2005) 2.88
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med (2009) 2.79
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Cardiovascular risk perception and evidence--practice gaps in Australian general practice (the AusHEART study). Med J Aust (2010) 2.62
Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA (2010) 2.61
Do we need to adjudicate major clinical events? Clin Trials (2008) 2.61
Overview of the Alberta Kidney Disease Network. BMC Nephrol (2009) 2.58
Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. Kidney Int (2008) 2.56
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med (2011) 2.48
A systematic review of the impact of adherence on the effectiveness of e-therapies. J Med Internet Res (2011) 2.47
Sequencing and automated whole-genome optical mapping of the genome of a domestic goat (Capra hircus). Nat Biotechnol (2012) 2.45
Rates of treated and untreated kidney failure in older vs younger adults. JAMA (2012) 2.43
Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J (2008) 2.41
Using verbal autopsy to measure causes of death: the comparative performance of existing methods. BMC Med (2014) 2.39
Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2007) 2.38
Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens (2006) 2.37
Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int (2004) 2.37
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2014) 2.35